Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
Actinic Keratosis
DRUG: Ingenol Mebutate|OTHER: Vehicle
Percentage of Participants With Complete Resolution of Actinic Keratosis (AK), Complete resolution of actinic keratosis (AKclear100) at Week 8 is defined as 100% reduction from baseline in the number of clinically visible AKs, 8 weeks
Percentage of Participants With Partial Clearance at Week 8, Partial clearance (AKclear75 ) is defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline., 8 weeks|Percentage of Participants With Partial Clearance at Week 4, Partial clearance (AKclear75) defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline., 4 weeks|Percent Reduction From Baseline in AK Count, Percent reduction in AK count in the selected treatment area at Week 8, 8 weeks
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.